272 related articles for article (PubMed ID: 22385406)
1. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
[TBL] [Abstract][Full Text] [Related]
2. Switching Between Epoetins: A Practice in Support of Biosimilar Use.
D'Amore C; Da Cas R; Rossi M; Traversa G
BioDrugs; 2016 Feb; 30(1):27-32. PubMed ID: 26728875
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
5. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
[TBL] [Abstract][Full Text] [Related]
7. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
8. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
[TBL] [Abstract][Full Text] [Related]
11. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
[TBL] [Abstract][Full Text] [Related]
12. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
[TBL] [Abstract][Full Text] [Related]
13. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Tari DU; Troncone C; Fontana A; Ientile V; Gini R; Santoro D; Santarpia M; Genazzani A; Uomo I; Pastorello M; Addario WS; Scondotto S; Cananzi P; Caputi AP; Trifirò G
BioDrugs; 2015 Aug; 29(4):275-84. PubMed ID: 26169209
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
Anand S; Al-Mondhiry J; Fischer K; Glaspy J
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
[No Abstract] [Full Text] [Related]
15. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.
Michallet M; Luporsi E; Soubeyran P; Amar NA; Boulanger V; Carreiro M; Dourthe LM; Labourey JL; Lepille D; Maloisel F; Mouysset JL; Nahon S; Narciso B; Nouyrigat P; Radji R; Sakek N; Albrand H;
BMC Cancer; 2014 Jul; 14():503. PubMed ID: 25011615
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic impact of epoetins in cancer care.
Marchetti M; Barosi G
Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
[TBL] [Abstract][Full Text] [Related]
17. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
19. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]